代表論文

2022年

  • Onishi H, Iwamoto N, Sakanashi K, Koga S, Oyama Y, Yanai K, Nakamura K, Nagai S, Fujimura A, Nakayama K, Ozono K, Yamasaki A. PTPN3 could be a therapeutic target of pancreatic cancer. Anticancer Res, In press
  • Morisaki T, Morisaki T, Kubo M, Morisaki S, Nakamura Y, Onishi H. Lymph nodes as anti-tumor immunotherapeutic tool: intranodal tumor-specific antigen-pulsed dendritic cell vaccine immunotherapy. Cancers, In press
  • Guan W, Nakata K, Sagara A, Endo S, Iwamoto C, Ikenaga N, Shindo K, Moriyama T, Matsuda R, Onishi H, Ohuchida K, Mizumoto K, Oda Y, Nakamura M. Erap2 affects pancreatic stellate cells activation via autophagy. Pancreatology 22(1): 9-19, 2022.
  • Ichimiya S, Fujimura A, Masuda M, Masuda S, Yasumatsu R, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Yoshimura S, Onishi H, Nakamura M, Nakamura Y, Morisaki T. Contribution of pre-existing neoantigen-specific T cells to durable complete responses after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma. Immunol Invest, In press
  • Onishi H, Nakamura K, Yanai K, Nagai S, Nakayama K, Oyama Y, Fujimura A, Ozono K, Yamasaki A. Cancer therapy that targets the HEDGEHOG signaling pathway considering the cancer microenvironment. Oncol Rep, In press
  • 村橋睦了、大山康博、大西秀哉、高崎 凌、草森浩輔、西川元也:膵癌に対する線維化抑制ペプチドとT細胞輸注療法併用免疫療法の開発. JRAI Report 9: 13-18, 2022.

2021年

  • Morisaki T, Hikichi T, Onishi H, Morisaki T, Kubo M, Hirano T, Yoshimura S, Kiyotani K, Nakamura Y. Intranodal administration of neoantigen peptide-loaded dendritic cell vaccine elicits epitope-specific T cell responses and clinical effects in a patient with chemorefractory ovarian cancer with malignant ascites. Immunol Invest 50(5): 562-579, 2021.
  • Ichimiya S, Onishi H, Nagao S, Koga S, Sakihama K, Nakayama K, Fujimura A, Oyama Y, Imaizumi A, Oda Y, Nakamura M. GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer. Oncol Rep 45: 997-1010, 2021.
  • Sekino Y, Imaizumi A, Komune N, Ono M, Sato K, Masuda S, Fujimura A, Koike K, Hongo T, Uchi R, Onishi H, Nakagawa T. Establishment and characterization of a primary cell culture derived from external auditory canal squamous cell carcinoma. FEBS open Bio. 11: 2211-24, 2021.
  • Koga S, Onishi H, Masuda S, Fujimura A, Ichimiya S, Nakayama K, Imaizumi A, Nishiyama K, Kojima M, Miyoshi K, Nakamura K, Umebayashi M, Morisaki T, Nakamura M. PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor. Transl Oncol 14(9): 101152, 2021.
  • Oyama Y, Nagao S, Na L, Yanai K, Umebayashi M, Nakamura K, Nagai S, Fujimura A, Nakayama K, Morisaki T, Onishi H. TrkB/BDNF signaling could be a new therapeutic target for pancreatic cancer. Anticancer Res 41(8): 4047-52, 2021.
  • Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, Eto M, Monji K, Takeuchi A, Nakagawa S, Tanaka H, Koya N, Umebayashi M, Tsujimura K, Yew PY, Yoshimura S, Kiyotani K, Nakamura Y. Efficacy of intranodal neoantigen peptide-pulsed dendritic cell vaccine monotherapy in patients for advanced solid tumors; retrospective analysis. Anticancer Res 41(8): 4101-15, 2021.

2020年

  • Oyama Y, Onishi H, Koga S, Murahashi M, Ichimiya S, Nakayama K, Fujimura A, Kawamoto M, Imaizumi A, Umebayashi M, Ohuchida K, Morisaki T, Nakamura M. Patched 1-interacting peptide represses fibrosis in pancreatic cancer to augment the effectiveness of immunotherapy. J Immunother 43(4): 121-133, 2020.
  • Saeki K, Onishi H, Koga S, Ichimiya S, Nakayama K, Oyama Y, Kawamoto M, Sakihama K, Yamamoto T, Matsuda R, Miyasaka Y, Nakamura M, Oda Y. FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patients. J Cancer 11(8): 2289-2302, 2020.
  • Nakayama K, Onishi H, Fujimura A, Imaizumi A, Kawamoto M, Oyama Y, Ichimiya S, Koga S, Fujimoto Y, Nakashima K, Nakamura M. NFκB and TGFβ contribute to the expression of PTPN3 in activated human lymphocytes. Cell Immunol 358: 104237, 2020.
  • Yamasaki A, Yanai K, Onishi H. Hypoxia and pancreatic ductal adenocarcinoma. Cancer Lett 484 9-15, 2020.

2019年

  • Fujimura A, Nakayama K, Imaizumi A, Kawamoto M, Oyama Y, Ichimiya S, Umebayashi M, Koya N, Morisaki T, Nakagawa T, Onishi H. PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody type immune checkpoint inhibitor. Cancer Immunol Immunother 68(10): 1649-60, 2019.
  • Nakamura S, Sadakari Y, Ohtsuka T, Okayama T, Nakashima Y, Gotoh Y, Saeki K, Mori Y, Nakata K, Miyasaka Y, Onishi H, Oda Y, Goggins M, Nakamura M. Pancreatic juice exosomal microRNAs as sensitive biomarkers for detection of pancreatic ductal adenocarcinoma. Ann Surg Oncol 26(7): 2104-11, 2019.
  • Onishi H, Yamasaki A, Nakamura K, Ichimiya S, Yanai K, Umebayashi M, Nagai S, Morisaki T. Liprin-α4 as a new therapeutic target for SCLC as an upstream mediator of HIF1α. Anticancer Res 39(3): 1179-84, 2019.

2018年

  • Kawamoto M, Wada J, Koya N, Takami Y, Saitsu H, Ishizaki N, Tabata M, Onishi H, Nakamura M, Morisaki T: Long-term survival of a patient with recurrent gallbladder carcinoma, treated with chemotherapy, immunotherapy, and surgery: a case report. Surg Case Rep 4(1): 115, 2018
  • Onishi H, Ichimiya S, Yanai K, Umebayashi M, Nakamura K, Yamasaki A, Imaizumi A, Nagai S, Murahashi M, Ogata H, Morisaki T: RBPJ and MAML3: Potential therapeutic targets for small cell lung cancer. Anticancer Res 38(8) 4543-7, 2018
  • Kubo M, Umebayashi M, Kurata K, Mori H, Kai M, Onishi H, Katano M, Nakamura M, Morisaki T: Catumaxomab with activated T-cells efficiently lyses chemoresistant EpCAMpositive triple-negative breast cancer cell lines. Anticancer Res 38(7) 4273-9, 2018
  • 大西秀哉、森崎 隆:化学療法と免疫療法、消化器外科 41: 491-6, 2018
  • Kawamoto M, Ozono K, Oyama Y, Yamasaki A, Oda Y, Onishi H: The novel selective pan-TRK inhibitor ONO-7579 exhibits antitumor efficacy against human gallbladder cancer in vitro. Anticancer Res 38(4), 1979-86, 2018.
  • Kawamoto M, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Kawabe K, Onishi H, Nakamura M, Morisaki T: Combined gemcitabine and metronidazole is a promising therapeutic strategy for cancer stem-like cholangiocarcinoma. Anticancer Res 38(5), 2739-48, 2018

2017年

  • 大西秀哉、荻野利達、森崎 隆、片野光男:患者さんを見据えた全人的癌治療―低酸素環境とHedgehog Signal―癌と化学療法 44: 977-80, 2017.
  • Kawamoto M, Onishi H, Koya N, Konomi H, Mitsugi K, Tanaka R, Motoshita J, Morisaki T, Nakamura M: Stage IV gastric cancer successfully treated multidisciplinary therapy including immunotherapy: a case report. Surg Case Rep 3(1): 112, 2017.
  • Onishi H. Future prospect of gallbladder therapy using Hedgehog signaling inhibitor. Chin Clin Oncol. 6(1): 11, 2017
  • Onishi H, Suyama K, Yamasaki A, Oyama Y, Fujimura A, Kawamoto M, Imaizumi A: CD24 Modulates Chemosensitivity of MCF-7 Breast Cancer cells. Anticancer Res 37(2): 561-5, 2017.
  • Kawamoto M, Onishi H, Ozono K, Yamasaki A, Imaizumi A, Kamakura S, Nakano K, Oda Y, Sumimoto H, Nakamura M. Tropomyosin-related kinase B mediated signaling contributes to the induction of malignant phenotype of gallbladder cancer. Oncotarget 8(22): 36211-24, 2017.
  • Ozono K, Ohishi Y, Onishi H, Nakamura K, Motoshita J, Kato M, Nakanishi Y, Nakamura M, Oda Y. Brain-derived neurotrophic factor / tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma. Lab Invest. 97(11): 1332-42, 2017.
  • Onishi H, Nakamura K, Nagai S, Yanai K, Yamasaki A, Kawamoto M, Imaizumi A, Morisaki T. Hedgehog inhibition upregulates TRKB expression to antagonize tumor suppression in small cell lung cancer cells. Anticancer Res 37 (9): 4987-92, 2017.
  • Yamasaki A, Nakayama K, Imaizumi A, Kawamoto M, Fujimura A, Oyama Y, Nagai S, Yanai K, Onishi H. Liprin-α4 as a possible new therapeutic target for pancreatic cancer. Anticancer Res 37(12): 6649-54, 2017.
このページの先頭へ

2016年

  • Onishi H, Fujimura A, Oyama Y, Yamasaki A, Imaizumi A, Kawamoto M, Katano M, Umebayashi M, Morisaki T: Hedgehog signaling regulates PDL-1 expression in cancer cells to induce anti-tumor activity by activated lymphocytes. Cell Immunol 310:199-204, 2016
  • Onishi H, Morisaki T, Katano M: Regulatory T Cells: Immunotherapy of Cancer: An Innovative Treatment Comes of Age., Springer Japan, Tokyo, pp309-22, 2016(分担執筆)
  • Yamasaki A, Onishi H, Imaizumi A, Kawamoto M, Fujimura A, Oyama Y, Katano M: Protein-bound polysaccharide-K inhibits Hedgehog signaling through down-regulation of MAML3 and RBPJ transcription under hypoxia, suppressing the malignant phenotype in pancreatic cancer. Anticancer Res 36(8):3945-52, 2016.
  • Nakamura K, Miyoshi K, Onishi H. Future view of safe, painless and curative video assisted thoracoscopic surgery for lung cancer. Video-assist Thorac Surg. August 16, 2016
  • Yamasaki A, Onishi H, Yamamoto H, Ienaga J, Nakafusa Y, Terasaka R, Nakamura M: Asymptomatic adenocarcinoma arising from a gastric duplication cyst. Int J Surg Case Rep 25: 16-20, 2016.
  • Shinkai K, Nakano K, Cui L, Mizuuchi Y, Onishi H, Oda Y, Obika S, Tanaka M, Katano M: Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models. Int J Cancer, 139 (2): 433-45, 2016.
  • Suyama K, Onishi H, Imaizumi A, Shinkai K, Umebayashi M, Kubo M, Mizuuchi Y, Oda Y, Tanaka M, Nakamura M, Katano M: CD24 suppresses malignant phenotype by downregulation of SHH transcription through STAT1 inhibition in breast cancer cells. Cancer Lett, 374(1): 44-53, 2016
  • Imaizumi A, Onishi H, Yamasaki A, Kawamoto M, Umebayashi M, Morisaki T, Hasumi K: Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line. Anticancer Res, 36(2): 653-7, 2016
  • Onishi H, Yamasaki A, Kawamoto M, Imaizumi A, Katano M: Hypoxia but not normoxia promotes Smoothened transcription through upregulation of RBPJ and Mastermind-like 3 in pancreatic cancer. Cancer Lett, 371(2): 143-50, 2016

2015年

  • Kato M, Onishi H, Furugaki K, Yunotani S, Matsumoto K, Tsuruta N, Nakamura K, Katano M: New approach to complete video-assisted thoracoscopic lobectomy in T2 and T3 non-small cell lung cancer. Anticancer Res, 35(6): 3585-9, 2015
  • 大西秀哉、森藤良浩、片野光男、中村雅史:低酸素環境と膵癌:形態形成シグナル経路の関与. 胆と膵 36(10): 1169-74, 2015
このページの先頭へ

2014年

  • Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M, Morisaki T: An epithelial cell adhesion molecule- and CD3 bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro. Anticancer Res, 34(8): 4509-20, 2014.
  • Onishi H, Kiyota A, Koya N, Tanaka H, Umebayashi M, Katano M, Morisaki T: Random Migration Contributes to Cytotoxicity of Activated CD8+ T-Lymphocytes but not NK cells. Anticancer Res, 34(8): 3947-56, 2014
  • Morisaki T, Hirano T, Koya N, Kiyota A, Tanaka H, Umebayashi M, Onishi H, Katano M: NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors. Anticancer Res, 34(8): 4529-38, 2014.
  • Onishi H, Sumiyoshi K, Terasaka R, Katano M: Surgical Treatment to Aid Patients with Colorectal Perforation. In Vivo, 28(5): 997-1000, 2014
  • Kato M, Onishi H, Matsumoto K, Motoshita J, Tsuruta N, Higuchi K, Katano M: Prognostic Significance of Urine N1,N12-Diacetylspermine in Patients with Non-small Cell Lung Cancer. Anticancer Res, Anticancer Res 34(6): 3053-60, 2014.
  • Matsushita S, Onishi H, Nakano K, Nagamatsu I, Imaizumi A, Hattori M, Oda Y, Tanaka M, Katano M: The Hedgehog Signaling Pathway is a Potential Therapeutic Target for Gallbladder Cancer. Cancer Sci 105(3): 272-80, 2014
  • Morifuji Y, Onishi H, Iwasaki H, Imaizumi A, Nakano K, Tanaka M, Katano M: Reoxygenation from chronic hypoxia promotes metastatic processes in pancreatic cancer through the Hedgehog signaling. Cancer Sci 105(3): 324-33, 2014
  • Nagamatsu I, Onishi H, Matsushita S, Kubo M, Kai M, Imaizumi A, Nakano K, Hattori M, Oda Y, Tanaka M, Katano M:Notch4 is a potential therapeutic target for triple-negative breast cancer. Anticancer Res 34(1): 69-80, 2014
  • Onishi H, Katano M:The Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer. World J Gastroenterol 20(9) 2335-42, 2014
このページの先頭へ

2013年

  • Onishi H, Morisaki T, Kiyota A, Koya N, Tanaka H, Umebayashi M, Katano M:The Hedgehog inhibitor suppresses the function of monocyte-derived dendritic cells from patients with advanced cancer under hypoxia. Biochem Biophys Res Commun 436(1): 53-9, 2013
  • Onishi H, Morisaki T, Kiyota A, Koya N, Tanaka H, Umebayashi M, Katano M:The Hedgehog inhibitor cyclopamine impairs the benefits of immunotherapy with activated T and NK lymphocytes derived from patients with advanced cancer. Cancer Immunol Immunother 62(6): 1029-39, 2013
  • Suzuki H, Onishi H, Morisaki T, Tanaka M, Katano M: Intratumoral FOXP3+VEGFR2+ Regulatory T Cells Are Predictive Markers for Recurrence and Survival in Patients with Colorectal Cancer. Clin Immunol 146(1): 26-33, 2013
  • Odate S, Onishi H, Nakamura K, Kojima M, Uchiyama A, Kato M, Katano M: Tropomyosine related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma. Anticancer Res 33(9): 3699-703, 2013
  • Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M: Combining celecoxib with sorafenib synergistically inhibits hepatocellular cells in vitro. Anticancer Res 33(4): 1387-95, 2013
  • Onishi H, Morisaki T, Nakao F, Odate S, Morisaki T, Katano M:Protein-bound polysaccharide decreases invasiveness and proliferation in pancreatic cancer by inhibition of hedgehog signaling and HIF-1 pathways under hypoxia. Cancer Lett 335(2): 289-98, 2013
  • Odate S, Nakamura K, Onishi H, Kojima M, Uchiyama A, Nakano K, Kato M, Tanaka M, Katano M:TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell meuroendocrine carcinoma. Lung Cancer 79(3): 205-14, 2013
  • Iwasaki H, Nakano K, Shinkai K, Kunisawa Y, Hirahashi M, Oda Y, Onishi H, Katano M: Hedgehog Gli3 activator signal augments tumorigenicity of colorectal cancer via up-regulation of adherence-related genes. Cancer Sci 104(3): 328-36, 2013
このページの先頭へ

2012年

  • Morisaki T, Onishi H, Katano M: Cancer immunotherapy using NKG2D and DNAM-1 systems. Anticancer Res 32(6) 2241-7, 2012
  • Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M. Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro. Anticancer Res 32(6) 2249-56, 2012.
  • Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, Katano M, Morisaki T. A new method for rapid cytotoxic T-lymphocyte induction using a multiple cytokine cocktail. Anticancer Res 32(6) 2385-90, 2012.
  • Onishi H, Morisaki T, Katano M. Immunotherapy approaches targeting regulatory T-cells. Anticancer Res 32(3) 997-1003, 2012.
  • Ogino T, Onishi H, Suzuki H, Morisaki T, Tanaka M, Katano M. Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions. Cancer Immunol Immunother. 61(3) 409-24, 2012.
  • Onishi H, Morifuji Y, Kai M, Suyama K, Iwasaki H, Katano M. Hedgehog inhibitor decreases chemosensitivity to 5-FU and gemcitabine under hypoxic conditions in pancreatic cancer. Cancer Sci. 103(7) 1272-9, 2012
  • Kubo M, Onishi H, Kuroki S, Okido M, Shimada K, Yokohata K, Umeda S, Ogawa T, Tanaka M, Katano M. Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res 32(6) 2331-6, 2012.
  • Kato M, Onishi H, Matsumoto K, Tsuruta N, Higuchi K, Motoshita J, Katano M. Preoperative Chemoradiotherapy Using Cisplatin plus S-1 Can Induce Downstaging in Patients with Locally Advanced (Stage III) Non-Small-Cell Lung Cancer. Anticancer Res 32(11) 5099-104, 2012
このページの先頭へ

2011年

  • Onishi H, Morisaki T, Baba E, Nakamura M, Inaba S, Kuroki H, Matsumoto K, Katano M: Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma. Anticancer Res 31: 3995-4005. 2011.
  • Morisaki T, Onishi H, Koya N, Kiyota H, Tanaka M, Umebayashi M, Ogino T, Nagamatsu I, Katano M. Combinational cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system. Anticancer Res 31: 2505-10, 2011.
  • Yamasaki A, Onishi H, Morisaki T, Katano M. Induction of cytotoxic T lymphocytes by CEA peptide-pulsed γδ T cells isolated from patients with advanced cancer. Anticancer Res 31: 2419-24, 2011.
  • 加藤雅人、大西秀哉、鈴木宏往、鶴田伸子、樋口和行、片野光男 「肺癌における癌マーカーとしての尿中ジアセチルスペルミンの臨床的意義」肺癌 51(7) 787-92, 2011.
  • Onishi H, Katano M. Hedgehog signaling pathway as a therapeutic target in various types of cancer. Cancer Sci. 102(10) 1756-60, 2011.
  • Kitaura Y, Chikazawa N, Tasaka T, Nakano K, Tanaka M, Onishi H, Katano M. Transforming Growth Factor β1 Contributes to the Invasiveness of Pancreatic Ductal Adenocarcinoma Cells Through the Regulation of CD24 Expression. Pancreas 40(7) 1034-42, 2011.
  • Xu R, Nakano K, Iwasaki H, Kumagai M, Wakabayashi R, Yamasaki A, Suzuki H, Mibu R, Onishi H, Katano M: Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer. Cancer Lett. 306(2) 151-60, 2011.
  • Kai M, Onishi H, Souzaki M, Tanaka H, Kubo M, Tanaka M, Katano M. Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue by a newly developed fluorescence immunohistochemical staining method. Cancer Sci. 102(12) 2132-8, 2011.
  • Onishi H, Morisaki T, Nakafusa Y, Nakashima Y, Yokohata K, Katano M.Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. Int J Clin Oncol 16(6) 718-21, 2011
  • Onishi H, Kai M, Odate S, Iwasaki H, Morifuji Y, Ogino T, Morisaki T, Nakashima Y, Katano M.Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci. 102:1144-50,2011.
  • Souzaki M, Kubo M, Kai M, Kameda C, Tanaka H, Taguchi T, Tanaka M, Onishi H, Katano M. Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer. Cancer Sci. 102: 373-381, 2011
このページの先頭へ

2010年

  • Yamasaki A, Kameda C, Xu R, Tanaka H, Tasaka T, Chikazawa N, Suzuki H, Morisaki T, Kubo M, Onishi H, Tanaka M, Katano M: Nuclear factor kappaB-activated monocytes contribute to pancreatic cancer progression through the production of Shh. Cancer immunol. Immunother. 59: 675-86, 2010
  • Wada J, Onishi H, Suzuki H, Yamasaki A, Nagai S, Morisaki T, Katano M
    Surface-bound TGF-β1 on effusion-derived exosomes participates in the maintenance of both number and suppressive function of regulatory T cells in malignant effusions. Anticancer Res. 30(Sep):3747-57,2010
  • Tasaka T, Akiyoshi T, Yamaguchi K, Tanaka M, Onishi H, Katano M. Gamma-secretase complexes regulate the responses of human pancreatic ductal adenocarcinoma cells to taxanes. Anticance Res. 30(Dec): 4999-5010, 2010.
  • Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, Katano M. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res. Jun 30 (6):2041-8, 2010
  • Kameda C, Nakamura M, Tanaka H, Yamasaki A, Kubo M, Tanaka M, Onishi H, Katano M: Oestrogen receptor-α contributes to the regulation of hedgehog signaling pathway in ER α positive gastric cancer. Brt J Cancer. 102: 738-47, 2010
  • Suzuki H, Onishi H, Wada J, Yamasaki A, Tanaka H, Nakano K, Morisaki T, Katano M.: Vascular endothelial growth factor receptor 2 (VEGFR2) is selectively expressed by FOXP3highCD4+ regulatory T cells. , Eur J Immunol 40(1):197-203,2010
  • Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, Sozaki M, Tanaka M, Onishi H, Morisaki T, Katano M.: Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer. ,Cancer Immunol Immunother 59(5):653-61,2010
このページの先頭へ

2009年

  • Wada J, Suzuki H, Fuchino K, Tasaka T, Chikazawa N, Ikebe M, Kameda C, Tanaka H, Yamasaki A, Nagai S, Yanai K, Koga K, Nakamura M, Tanaka M, Katano M, Morisaki T: The contribution of vascular endothelial growth factor to the induction of regulatory T cells in malignant effusions,Anticancer Res 29: 881-8,2009
  • Ikebe M, Kitaura Y, Nakamura M, Tanaka H, Yamasaki A, Nagai S, Wada J, Yanai K, Koga K, Sato N, Kubo M, Tanaka M, Onishi H, Katano M.: Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway.,J Surg Oncol. 100: 725-31,2009
  • Tanaka H, Nakamura M, Kameda C, Kubo M, Sato N, Kuroki S, Tanaka M, Katano M.: The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells.,Anticancer Res 29:2147-57,2009
  • Masafumi Nakamura, Junji Wada, Hiroyuki Suzuki, Masao Tanaka, Mitsuo Katano, Takashi Morisaki: Long-term Outcome of Immunotherapy for Patients with Refractory Pancreatic Cancer,Anticancer Res 29: 831-6,2009
  • Rui Xu, Norihiro Sato, Kosuke Yanai, Takashi Akiyoshi, Shuntaro Nagai, Junji Wada, Kenichiro Koga, Ryuichi Mibu, Masafumi Nakamura, Mitsuo Katano : Enhancement of Paclitaxel-induced Apoptosis by Inhibition of Mitogen-activated Protein Kinase Pathway in Colon Cancer Cells,Anticancer Res 29(1): 261-70,2009
  • Akio Yamasaki, Makoto Shoda, Hiroko Iijima, Shuntaro Nagai, Junji Wada, Hiroyuki Suzuki, Nobuhiko Chikazawa, Takehiko Tasaka, Chizu Kameda, Haruo Tanaka, Mio Ikebe, Ei Jo, Norihiro Sato, Masafumi Nakamura, Fujio Sekine, Takashi Morisaki, Mitsuo Katano: A protein-bound polysaccharide, PSK, enhances tumor suppression induced by docetaxel in a gastric cancer xenograft model,Anticancer Res 29: 843-50,2009
  • Kameda C, Tanaka H, Yamasaki A, Nakamura M, Koga K, Sato N, Kubo M, Kuroki S, Tanaka M, Katano M: The hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer,Anticancer Res 29: 871-80,2009